About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer

NCT00073151·17 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Abbott

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Stage IIIB or IV non-small cell lung cancer.
Recurrent tumor following treatment with paclitaxel or docetaxel.
Able to tolerate normal activities of daily living.
Adequate bone marrow, kidney and liver function.

You may not be if

Pregnant or breast feeding.
Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
CNS metastasis.

The record

StatusCompleted

PhasePhase 2

Taking part30

StartedSep 2003

UpdatedNov 29, 2007

Conditions

Non-Small Cell Lung Cancer

Where17

Oncology Hematology Group of South Florida
Miami, Florida, United States
Florida Cancer Institute
New Port Richey, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States

Clareo Health | A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer